ARV-825
货号： abs812119
| 货号-规格 | 货期 | 价格 | 数量 |
| abs812119-5mg | 1-2周 | ￥4245.00 | - + |
| abs812119-10mg | 1-2周 | ￥6791.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | ARV-825是BRD4抑制剂, 作用于Burkitt淋巴瘤细胞, DC50 (50%最大降解率) ＜1nM, 对BD1和BD2的亲和力分别为90和28 nM。 | |
| 纯度 | 98% min | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 可溶性/溶解性 | 10 mM in DMSO | |
| 生物活性 | ||
| 靶点 | Epigenetic Reader Domain | |
| In vitro(体外研究) | ARV-825 is a hetero-bifunctional proteolysis-targeting chimera (PROTAC) that recruits BRD4 to the E3 ubiquitin ligase cereblon. ARV-825 actively recruits BRD4 to cereblon, resulting in the rapid and efficient degradation of the former via the proteasome. Given that BRD4 and cereblon binding moieties in ARV-825 have Kds of 28-90 nM and ~3 µM to their respective targets, this suggests that ARV-825 acts in a substoichiometric way in mediating BRD4 degradation. ARV-825 treatment results in prolonged BRD4 down-regulation and downstream signaling suppression compared to BRD4 inhibitors. | |
| 参考文献 | ||
| 参考文献 | [1]. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-763. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0张，还能上传 8张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要提问”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
